Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Pimicotinib Capsules in Healthy Subjects
NCT07126249Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at 240 hours and Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration at 240 hours. Started May 2025; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT07126249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126249.